Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine

• Published in: Current drug targets Vol. 20; no. 15; p. 1505
• Main Authors: Zhang, Yangyang, Liu, Minghua, Wang, Jun, Huang, Jianlin, Guo, Mingyue, Zuo, Ling, Xu, Biantiao, Cao, Shousong, Lin, Xiukun
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2019
• Subjects: PI3K/AKT/mTOR; anticancer activity; MAPK; Traditional chinese medicine; protein kinase inhibitors; ERK
• ISSN: 1873-5592
• DOI: 10.2174/1389450120666190802125959

Protein kinases play critical roles in the control of cell growth, proliferation, migration, and angiogenesis, through their catalytic activity. Over the past years, numerous protein kinase inhibitors have been identified and are being successfully used clinically. Traditional Chinese medicine (TCM) represents a large class of bioactive substances, and some of them display anticancer activity via inhibiting protein kinases signal pathway. Some of the TCM have been used to treat tumors clinically in China for many years. The p38mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase, serine/threonine-specific protein kinases (PI3K/AKT/mTOR), and extracellular signal-regulated kinases (ERK) pathways are considered important signals in cancer cell development. In the present article, the recent progress of TCM that exhibited significant inhibitory activity towards a range of protein kinases is discussed. The clinical efficacy of TCM with inhibitory effects on protein kinases in treating a tumor is also presented. The article also discussed the prospects and problems in the development of anticancer agents with TCM.